Non-small Cell Lung Cancer study: Pumitamig vs Durvalumab
Official title A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
ClinicalTrials.gov ID: NCT07361497
What this study is testing
What is Pumitamig?
Pumitamig is an investigational medicine, being studied as a potential treatment for non-small cell lung cancer (nsclc).
Also referred to as BMS-986545.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out whether Pumitamig works as well as or better than Durvalumab in preventing cancer from coming back after chemoradiation.
- Who it's for
- Adults who have unresectable stage III non‑small cell lung cancer and have finished concurrent chemoradiation therapy.
- What's involved
- Participants will receive either Pumitamig or Durvalumab by injection on a regular schedule, attend clinic visits for safety checks, and undergo imaging scans to monitor the cancer.
- Time commitment
- The trial lasts about two years, with clinic visits every few weeks for treatment and periodic scans.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III...
- Participants must have received at least 2 cycles of platinum-based concurrent chemoradiotherapy (a total dose of radiation of at least 54 Gy).
- Participants must have no progressive disease (PD) following treatment with concurrent chemoradiotherapy (CCRT).
- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.
You likely can't join if
- Participants with non-squamous histology must not have documented Epidermal Growth Factor Receptor (EGFR) and anaplastic lymphoma kinase (ALK)...
- Participants must not have an active autoimmune disease.
- Participants must not have significant cardiovascular impairment such as uncontrolled hypertension (despite optimal medical treatment), congestive...
- Participants must not have advanced/clinically significant lung disease (within 6 months prior to randomization) or history of interstitial lung...
- Participants must not have any prior anticancer therapy (outside of CCRT) for locally advanced Stage III disease.
- Other protocol-defined Inclusion/Exclusion criteria apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Daphne, Alabama, United States
- Golden, Colorado, United States
- Newark, Delaware, United States
- Tamarac, Florida, United States
- Marietta, Georgia, United States
- Chicago, Illinois, United States
- Evanston, Illinois, United States
- Peoria, Illinois, United States
- Fort Wayne, Indiana, United States
- Lexington, Kentucky, United States
- Detroit, Michigan, United States
- Maple Grove, Minnesota, United States
- Minneapolis, Minnesota, United States
- Columbia, Missouri, United States
- New York, New York, United States
- Westbury, New York, United States
- Winston-Salem, North Carolina, United States
- Akron, Ohio, United States
- Cincinnati, Ohio, United States
- Cleveland, Ohio, United States
+ 159 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Daphne, Alabama, United States; Golden, Colorado, United States; Newark, Delaware, United States; Tamarac, Florida, United States; Marietta, Georgia, United States; Chicago, Illinois, United States and 173 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.